

Life Sciences Executive Cathy Burzik Joins Gemini Board as Executive Chairman

**Cathy Burzik, current Director at Becton Dickinson and former CEO of Kinetic Concepts, named Executive Chairman of Gemini Bio-Products*

West Sacramento, CA, January 31, 2019 – Gemini Bio-Products today announced that seasoned life sciences executive Cathy Burzik has joined the Board of Directors as Executive Chairman of Gemini Bio-Products (“Gemini”), a BelHealth Investment Partners portfolio company based in West Sacramento, California. Gemini is a leading biological reagents manufacturer and supplier serving the scientific community across academic research and the biotechnology and biopharma industries.

Ms. Burzik has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Until its sale in 2012 to Apex Partners, Burzik served as President, Chief Executive Officer and Director of Kinetic Concepts, Inc., a medical device company specializing in wound care and regenerative medicine. Her prior positions include President of Applied Biosystems Group, a pioneer DNA sequencing company, President of Ortho Clinical Diagnostics and Critikon divisions of Johnson & Johnson (NYSE: JNJ), and senior positions with MITRE Corporation and Eastman Kodak Company (NYSE: KODK).

Ms. Burzik currently serves on the Boards of Directors of Becton Dickinson & Company (NYSE: BDX), Haemonetics Corporation (NYSE: HAE) and Xenex Disinfection Services, and is Chairman of the Board of Directors of StemBioSys, Inc., a life science tool and reagents company specializing in stem and progenitor cells. She previously served on the Boards of Directors of Allscripts (NASDAQ: MDRX), Bausch and Lomb, Cordis Corporation, the San Antonio Branch of the Dallas Federal Reserve Board, Innovative Trauma Care Ltd., Kinetic Concepts, Inc., and VitaPath Genetics, Inc.

In her leadership role on the Gemini board, Burzik will offer strategic counsel and insights to better serve the needs of research, development, and production across the globe. Her multi-disciplinary perspective in life sciences will enable Gemini to further grow and differentiate across a broader product portfolio. With best practices in corporate governance refined through experience across a number of life science boards, Burzik will work with management in reviewing plans, identifying issues, and maintaining accountability throughout the organization. Additionally, she will support collaboration between Gemini and StemBioSys.

Dale Gordon, Chief Executive Officer of Gemini, stated “Over the last 40 years, Cathy has built exceptional mastery across numerous life sciences companies that will champion Gemini’s growth within the broader cell and gene therapy sectors. I am thrilled to gain Cathy’s counsel and unique perspective as we continue to build Gemini into a leading bio-products company. Gemini’s partnership with StemBioSys will be bolstered by having a Board Chairman in common, as we further explore our strategic alliance in stem cell reagents.”

Cathy Burzik, added “I am delighted to join the Board of Gemini Bio-Products through the next chapter of its journey. For the past three decades, Gemini has built an excellent reputation as a supplier of quality reagents. Through my discussions with Gemini, Dale Gordon and his management team have proven to be exceptional in leading their respective organizations and I am excited to work closely with them. In partnership with StemBioSys, we intend to support burgeoning scientific innovation from around the globe in the fields of regenerative medicine, cancer immunotherapy, and gene therapy.”

In September 2018, Gemini Bio-Products partnered with BelHealth Investment Partners to accelerate growth and add to its manufacturing and quality capabilities. Harold S. Blue, Managing Partner of BelHealth stated, “We are thrilled to welcome Cathy to the Board of Gemini. With her current experience on the boards of Becton Dickinson and StemBioSys, and a deep understanding of Gemini’s product offerings, Cathy’s knowledge positions us well to scale Gemini into a leading reagents business alongside the rapid pace of innovation in the biotechnology community. Our investment in Gemini has just begun, and we are excited to continue our partnership with the management team in this endeavor. The addition of Cathy will take the platform to the next level as we grow both organically and through accretive acquisitions to enhance Gemini’s product offerings and capabilities.”

About Gemini Bio-Products

Founded in 1985, Gemini is a supplier of cell culture media, sera, and other reagents to many of the world’s top research and academic communities, biotechnology firms, and pharmaceutical companies. Today, Gemini operates from a 14,000 square foot manufacturing facility in West Sacramento, California. A national sales force and an international distribution network serves cell culture laboratories worldwide.

About BelHealth Investment Partners

BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm invests across three core healthcare segments: Services, Products and Distribution. BelHealth is investing from its current \$350 million fund.

For further information, please visit:

BelHealth Investment Partners: www.belhealth.com

Contact:

BelHealth Investment Partners: Inder Tallur (347) 308-7018

Gemini Bio-Products: Dale Gordon (916) 273-5228